FDG PET and PET/CT imaging in lymphoma and melanoma

Cancer Journal

Volumn 10, Issue 4, 2004, Pages 262-270

  Macapinlac, Homer A ^a,b  

^a University of Texas MD Anderson Cancer Center ^*

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Curative radiation; Functional imaging; Tumor

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HUMAN; LYMPHOMA; MEDICAL ASSESSMENT; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TUMOR BIOPSY; IMAGE PROCESSING; REVIEW; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LYMPHOMA; MELANOMA; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 16644392704     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200407000-00007     Document Type: Article

References (25)

1. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111-116.
2. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34(9):1420-1427.
3. Bos R, van der Hoeven JJ, van der Wall E et al. Biologic correlates of 18-fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-387.
4. Wirth A, Seymour JF, Hicks RJ et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002;112:262-268.
5. Friedberg JW, Fischman A, Neuberg D et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004;45:85-92.
6. Young CS, Young BL, Smith SM. Staging Hodgkin's disease with 18-FDG PET: comparison with CT and surgery. Clin Pos Imag 1998;1:161-164.
7. Bangerter M, Kotzerke J, Griesshammer M et al. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999;38:799-804.
8. Roelcke U, Leenders KL. Positron emission tomography in patients with primary CNS lymphomas. J Neurooncol 1999;43:231-236.
9. Schoder H, Larson SM, Yeung HW. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004;45[Suppl 1]:72S-81S.
10. Yeung HW, Grewal RK, Gonen M et al. Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 2003;44:1789-1796.
11. Schaefer NG, Hany TF, Taverna C et al. Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 2004, in press (e-pub ahead of print at radiology.rsnajnls.org).
12. Bangerter M, Moog F, Griesshammer M et al. Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment. Radiography 1999;5:155-163.
13. Cremerius U, Fabry U, Neuerburg J et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nuc Med Commun 1998;19:1055-1063.
14. Naumann R, Vaic A, Beuthien-Baumann B et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001;115:793-800.
15. Spaepen K, Stroobants S, Dupont P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414-419.
16. Spaepen K, Stroobants S, Dupont P et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356-1363.
17. Macapinlac HA. The utility of 2-deoxy-2-[(18)F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma. Mol Imaging Biol 2004;6:200-207.
18. Blodgett TM, Ames JT, Torok FS, McCook BM, Meltzer CC. Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin. Clin Nucl Med 2004;29:161-163.
19. Balch CM, Buzaid AC, Soong S-J et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
20. Morton DL, Thompson JF, Essner R et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-463; discussion 463-465.
21. 18F-fluorodeoxyglucose positron emission tomography. Results of a prospective trial of 100 patients. Cancer 1998;82:1664-1671.
22. Crippa F, Leutner M, Belli F et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000;41:1491-1494.
23. Mijnhout GS, Hoekstra OS, van Lingen A et al. How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma. J Clin Pathol 2003;56:283-286.
24. Gulec SA, Faries MB, Lee CC et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 2003;28:961-965.
25. Finkelstein SE, Carrasquillo JA, Hoffman JM et al. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol 2004;11:731-738.